Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - verapamil hydrochloride, quantity: 240 mg - tablet, modified release - excipient ingredients: sodium alginate; powdered cellulose; purified water; magnesium stearate; hypromellose; purified talc; titanium dioxide; povidone; glycol/butylene glycol montanate; macrogol 400; macrogol 6000; quinoline yellow; indigo carmine - cordilox sr (verapamil hydrochloride) is indicated for the management of hypertension and angina pectoris.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - erythromycin ethyl succinate, quantity: 482.04 mg (equivalent: erythromycin, qty 400 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; povidone; maize starch; sorbic acid; calcium hydrogen phosphate; purified talc; magnesium stearate; titanium dioxide; iron oxide red; xanthan gum; polyvinyl alcohol; lecithin - streptococcus pyogenes (group a beta-haemolytic streptococcus). upper and lower respiratory tract, skin and skin structure infections of mild to moderate severity. when oral medication is given, patient must comply with the prescribed regimen. therapeutic dose should be administered for at least 10 days. alpha haemolytic streptococci (viridans group). no controlled clinical efficacy trials have been conducted, however oral erythromycin has been suggested by the american heart association and the american dental association for use in bacterial endocarditis prophylaxis prior to dental/surgical procedures of the upper respiratory tract in penicillin-hypersensitive patients with a history of rheumatic, congenital or other acquired valvular heart disease. erythromycin is unsuitable prior to genitourinary or gastrointestinal tract surgery. staphylococcus aureus. acute infections of skin and skin structure of mild to moderate severity. bacterial resistance may emerge during treatment, hence cultures and sensitivity tests should be performed. streptococcus pneumoniae (diplococcus pneumoniae). upper (e.g. otitis media, pharyngitis) and lower respiratory tract infections (e.g. pneumonia) of mild to moderate degree. mycoplasma pneumoniae (eaton agent, pplo). for respiratory infections due to this organism. haemophilus influenzae. for upper respiratory tract infections of mild to moderate severity. not all strains are susceptible at the erythromycin concentrations normally achieved. chlamydia trachomatis and ureaplasma urealyticum. these organisms are sensitive to erythromycin; clinical studies have demonstrated erythromycin's efficacy in nongonococcal urethritis due to these organisms. a minimum of 10 days therapy is required. chlamydia trachomatis infection (excluding nongonococcal urethritis). erythromycin has shown to be effective in treating trachoma or inclusion body conjunctivitis, acute inclusion conjunctivitis of the newborn (inclusion blennorrhoea) and pneumonia in infants caused by chlamydia trachomatis. treponema pallidum. erythromycin is an alternative drug in treating primary syphilis in patients allergic to penicillins. spinal fluid examinations should be done before treatment and as part of follow-up post therapy. neisseria gonorrhoeae. erythromycin lactobionate for injection in conjunction with oral erythromycin ethylsuccinate, as an alternative treatment for acute uncomplicated gonorrhoea in female patients with penicillin hypersensitivity. before treatment, patients who are suspected of also having syphilis should be evaluated including a microscopic examination for t. pallidum (by immunofluorescence or darkfield) before receiving erythromycin, and monthly serologic tests should be performed for a minimum of 4 months. corynebacterium diphtheriae, c. minutissimum and c. (propionibacterium) acnes. as an adjunct to diphtheria antitoxin, to prevent establishment of carriers, and to eradicate the organism in carriers; in the treatment of erythrasma; adjunctive therapy of moderate to severe acne. bordetella pertussis. for early elimination of the causative organism from the nasopharynx. therapeutic doses should be continued for at least 10 days. the clinical course of the disease is not altered. clostridium tetani. in vitro, clostridium tetani is sensitive to erythromycin. erythromycin may be used prophylatically in penicillin-hypersensitive persons for 5 days. as the value of antibiotic prophylaxis in tetanus is not unequivocally established, wounds should be regularly examined. legionnaires' disease. although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease. campylobacter fetus (subspecies) jejuni, listeria monocytogenes. infections due to this organism when antibiotic therapy is indicated.

Kenya - anglès - Pharmacy and Poisons Board

renata limited plot#1 milk vita road section-vii mirpur - tiemonium methylsulphate - film-coated tablet - tiemonium methylsulphate 50mg/tablet - drugs for functional gastrointestinal disorders:

Malta - anglès - Medicines Authority

alliance pharma (ireland) ltd - paracetamol, phenylephrine hydrochloride, caffeine, diphenhydramine hydrochloride, codeine phosphate - film-coated tablet - paracetamol 500 milligram(s) ; phenylephrine hydrochloride 10 milligram(s) ; caffeine 30 milligram(s) ; diphenhydramine hydrochloride 15 milligram(s) ; codeine phosphate 10 milligram(s) - analgesics

Malta - anglès - Medicines Authority

abbott laboratories limited - clarithromycin 250 mg - film-coated tablet

Malta - anglès - Medicines Authority

abbott laboratories limited - clarithromycin 500 mg - film-coated tablet

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

haleon australia pty ltd - paracetamol, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; colloidal anhydrous silica; magnesium stearate; purified water; crospovidone; pregelatinised maize starch; carnauba wax; alginic acid; calcium carbonate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - for the fast, effective relief of pain and discomfort associated with headache, tension headache, muscular aches, toothache, migraine headache, cold & flu symptoms, arthritis/osteoarthritis, backache, period pain. helps reduce fever.

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

phoenix labs - paracetamol; codeine phosphate hemihydrate; diphenhydramine hydrochloride; phenylephrine hydrochloride; caffeine; ascorbic acid - film-coated tablet + tablet - 30 mg/10 mg/15 mg/500 mg/10 milligram(s) - anilides; paracetamol, combinations excl. psycholeptics

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

phoenix labs - caffeine; diphenhydramine hydrochloride; paracetamol; phenylephrine hydrochloride; ascorbic acid - film-coated tablet + tablet - 30 mg/15 mg/500 mg/10 milligram(s) - anilides; paracetamol, combinations excl. psycholeptics

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - iron polymaltose, quantity: 370 mg (equivalent: iron, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; macrogol 6000; crospovidone; magnesium stearate; titanium dioxide; hypromellose; hyprolose; iron oxide yellow; iron oxide red - treatment of iron deficiency in adults and adolescents where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate. prevention of iron deficiency in adults and adolescents at high risk where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate.